GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy

References

• Crispino JD, Horwitz MS. GATA factor mutations in hematologic disease. Blood. 2017;129:2103–2110.
   PubMed Web of Science ®Google Scholar
• Kerenyi MA, Orkin SH. Networking erythropoiesis. J Exp Med. 2010;207:2537–2541.
   PubMed Web of Science ®Google Scholar
• Kadri Z, Shimizu R, Ohneda O, et al. Direct binding of pRb/E2F-2 to GATA-1 regulates maturation and terminal cell division during erythropoiesis. PLoS Biol. 2009;7:e1000123.
   PubMed Web of Science ®Google Scholar
• Migliaccio AR, Migliaccio G, Ashihara E, et al. Erythroid-specific activation of the distal (testis) promoter of GATA1 during differentiation of purified normal murine hematopoietic stem cells. Acta Haematol. 1996;95:229–235.
   PubMed Web of Science ®Google Scholar
• Attema JL, Papathanasiou P, Forsberg EC, et al. Epigenetic characterization of hematopoietic stem cell differentiation using miniChIP and bisulfite sequencing analysis. Proc Natl Acad Sci U S A. 2007;104:12371–12376.
   PubMed Web of Science ®Google Scholar
• Yu C, Cantor AB, Yang H, et al. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med. 2002;195:1387–1395.
   PubMed Web of Science ®Google Scholar
• Migliaccio AR, Rana RA, Sanchez M, et al. GATA-1 as a regulator of mast cell differentiation revealed by the phenotype of the GATA-1low mouse mutant. J Exp Med. 2003;197:281–296.
   PubMed Web of Science ®Google Scholar
• Ohneda K, Moriguchi T, Ohmori S, et al. Transcription factor GATA1 is dispensable for mast cell differentiation in adult mice. Mol Cell Biol. 2014;34:1812–1826.
   PubMed Web of Science ®Google Scholar
• Scheenstra MR, De Cuyper IM, Branco-Madeira F, et al. GATA1-deficient dendritic cells display impaired CCL21-dependent migration toward lymph nodes due to reduced levels of polysialic acid. J Immunol. 2016;197:4312–4324.
   PubMed Web of Science ®Google Scholar
• Kozma GT, Martelli F, Verrucci M, et al. Dynamic regulation of Gata1 expression during the maturation of conventional dendritic cells. Exp Hematol. 2010;38:489–503.e1.
   PubMed Web of Science ®Google Scholar
• Lee WY, Weinberg OK, Pinkus GS. GATA1 is a sensitive and specific nuclear marker for erythroid and megakaryocytic lineages. Am J Clin Pathol. 2017;147:420–426.
   PubMed Web of Science ®Google Scholar
• Shivdasani RA, Fujiwara Y, McDevitt MA, et al. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J. 1997;16:3965–3973.
   PubMed Web of Science ®Google Scholar
• Simon MC, Pevny L, Wiles MV, et al. Rescue of erythroid development in gene targeted GATA-1- mouse embryonic stem cells. Nat Genet. 1992;1:92–98.
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Browne CP, Cunniff K, et al. Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1. Proc Natl Acad Sci U S A. 1996;93:12355–12358.
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Zon LI, Ackerman SJ, et al. Forced GATA-1 expression in the murine myeloid cell line M1: induction of c-Mpl expression and megakaryocytic/erythroid differentiation. Blood. 1998;91:450–457.
   PubMed Web of Science ®Google Scholar
• Layon ME, Ackley CJ, West RJ, et al. Expression of GATA-1 in a non-hematopoietic cell line induces β-globin locus control region chromatin structure remodeling and an erythroid pattern of gene expression. J Mol Biol. 2007;366:737–744.
   PubMed Web of Science ®Google Scholar
• Visvader JE, Elefanty AG, Strasser A, et al. GATA-1 but not SCL induces megakaryocytic differentiation in an early myeloid line. Embo J. 1992;11:4557–4564.
   PubMed Web of Science ®Google Scholar
• Crispino JD, Weiss MJ. Erythro-megakaryocytic transcription factors associated with hereditary anemia. Blood. 2014;123:3080–3088.
   PubMed Web of Science ®Google Scholar
• Campbell AE, Wilkinson-White L, Mackay JP, et al. Analysis of disease-causing GATA1 mutations in murine gene complementation systems. Blood. 2013;121:5218–5227.
   PubMed Web of Science ®Google Scholar
• Calligaris R, Bottardi S, Cogoi S, et al. Alternative translation initiation site usage results in two functionally distinct forms of the GATA-1 transcription factor. Proc Natl Acad Sci U S A. 1995;92:11598–11602.
   PubMed Web of Science ®Google Scholar
• Chlon TM, McNulty M, Goldenson B, et al. Global transcriptome and chromatin occupancy analysis reveal the short isoform of GATA1 is deficient for erythroid specification and gene expression. Haematologica. 2015;100:575–584.
   PubMed Web of Science ®Google Scholar
• Byrska-Bishop M, VanDorn D, Campbell AE, et al. Pluripotent stem cells reveal erythroid-specific activities of the GATA1 N-terminus. J Clin Invest. 2015;125:993–1005.
   PubMed Web of Science ®Google Scholar
• Ludwig LS, Gazda HT, Eng JC, et al. Altered translation of GATA1 in Diamond-Blackfan anemia. Nat Med. 2014;20:748–753.
   PubMed Web of Science ®Google Scholar
• Gilles L, Arslan AD, Marinaccio C, et al. Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. J Clin Invest. 2017;127:1316–1320.
   PubMed Web of Science ®Google Scholar
• O’Brien KA, Farrar JE, Vlachos A, et al. Molecular convergence in ex vivo models of Diamond-Blackfan anemia. Blood. 2017;129:3111–3120.
   PubMed Web of Science ®Google Scholar
• Cantor AB, Orkin SH. Transcriptional regulation of erythropoiesis: an affair involving multiple partners. Oncogene. 2002;21:3368–3376.
   PubMed Web of Science ®Google Scholar
• Shimizu R, Yamamoto M. GATA-related hematologic disorders. Exp Hematol. 2016;44:696–705.
   PubMed Web of Science ®Google Scholar
• Bresnick EH, Lee HY, Fujiwara T, et al. GATA switches as developmental drivers. J Biol Chem. 2010;285:31087–31093.
   PubMed Web of Science ®Google Scholar
• Grass JA, Boyer ME, Pal S, et al. GATA-1-dependent transcriptional repression of GATA-2 via disruption of positive autoregulation and domain-wide chromatin remodeling. Proc Natl Acad Sci U S A. 2003;100:8811–8816.
   PubMed Web of Science ®Google Scholar
• Ohyashiki K, Ohyashiki JH, Shimamoto T, et al. Pattern of expression and their clinical implications of the GATA family, stem cell leukemia gene, and EVI1 in leukemia and myelodysplastic syndromes. Leuk Lymphoma. 1996;23:431–436.
   PubMed Web of Science ®Google Scholar
• Li Z, Godinho FJ, Klusmann JH, et al. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005;37:613–619.
   PubMed Web of Science ®Google Scholar
• Birger Y, Goldberg L, Chlon TM, et al. Perturbation of fetal hematopoiesis in a mouse model of Down syndrome’s transient myeloproliferative disorder. Blood. 2013;122:988–998.
   PubMed Web of Science ®Google Scholar
• Kadauke S, Blobel GA. “Remembering” tissue-specific transcription patterns through mitosis. Cell Cycle. 2012;11:3911–3912.
   PubMed Web of Science ®Google Scholar
• Kadauke S, Udugama MI, Pawlicki JM, et al. Tissue-specific mitotic bookmarking by hematopoietic transcription factor GATA1. Cell. 2012;150:725–737.
   PubMed Web of Science ®Google Scholar
• Lejon S, Thong SY, Murthy A, et al. Insights into association of the NuRD complex with FOG-1 from the crystal structure of an RbAp48·FOG-1 complex. J Biol Chem. 2011;286:1196–1203.
   PubMed Web of Science ®Google Scholar
• Ross J, Mavoungou L, Bresnick EH, et al. GATA-1 utilizes ikaros and polycomb repressive complex 2 to suppress Hes1 and to promote erythropoiesis. Mol Cell Biol. 2012;32:3624–3638.
   PubMed Web of Science ®Google Scholar
• Xu J, Shao Z, Li D, et al. Developmental control of polycomb subunit composition by GATA factors mediates a switch to non-canonical functions. Mol Cell. 2015;57:304–316.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wu WS, Kumar SA, et al. Erythroid GATA1 function revealed by genome-wide analysis of transcription factor occupancy, histone modifications, and mRNA expression. Genome Res. 2009;19:2172–2184.
   PubMed Web of Science ®Google Scholar
• Papadopoulos GL, Karkoulia E, Tsamardinos I, et al. GATA-1 genome-wide occupancy associates with distinct epigenetic profiles in mouse fetal liver erythropoiesis. Nucleic Acids Res. 2013;41:4938–4948.
   PubMed Web of Science ®Google Scholar
• Hong W, Nakazawa M, Chen YY, et al. FOG-1 recruits the NuRD repressor complex to mediate transcriptional repression by GATA-1. Embo J. 2005;24:2367–2378.
   PubMed Web of Science ®Google Scholar
• Yang T, Jian W, Luo Y, et al. Acetylation of histone deacetylase 1 regulates NuRD corepressor complex activity. J Biol Chem. 2012;287:40279–40291.
   PubMed Web of Science ®Google Scholar
• Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature. 2011;469:343–349.
   PubMed Web of Science ®Google Scholar
• Yu M, Riva L, Xie H, et al. Insights into GATA-1 mediated gene activation versus repression via genome-wide chromatin occupancy analysis. Mol Cell. 2009;36:682–695.
   PubMed Web of Science ®Google Scholar
• Yu W, Zhang F, Wang S, et al. Depletion of polycomb repressive complex 2 core component EED impairs fetal hematopoiesis. Cell Death Dis. 2017;8:e2744.
   PubMed Web of Science ®Google Scholar
• Varricchio L, Dell’Aversana C, Nebbioso A, et al. Identification of NuRSERY, a new functional HDAC complex composed by HDAC5, GATA1, EKLF and pERK present in human erythroid cells. Int J Biochem Cell Biol. 2014;50:112–122.
   PubMed Web of Science ®Google Scholar
• Han X, Zhang J, Peng Y, et al. Unexpected role for p19INK4d in posttranscriptional regulation of GATA1 and modulation of human terminal erythropoiesis. Blood. 2017;129:226–237.
   PubMed Web of Science ®Google Scholar
• Mundschau G, Crispino J. GATA1s goes germline. Nat Genet. 2006;38:741–742.
   PubMed Web of Science ®Google Scholar
• Sankaran VG, Ghazvinian R, Do R, et al. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest. 2012;122:2439–2443.
   PubMed Web of Science ®Google Scholar
• Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148–152.
   PubMed Web of Science ®Google Scholar
• Mundschau G, Gurbuxani S, Gamis AS, et al. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003;101:4298–4300.
   PubMed Web of Science ®Google Scholar
• Muntean AG, Crispino JD. Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. Blood. 2005;106:1223–1231.
   PubMed Web of Science ®Google Scholar
• Kuhl C, Atzberger A, Iborra F, et al. GATA1-mediated megakaryocyte differentiation and growth control can be uncoupled and mapped to different domains in GATA1. Mol Cell Biol. 2005;25:8592–8606.
   PubMed Web of Science ®Google Scholar
• Hollanda LM, Lima CS, Cunha AF, et al. An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet. 2006;38:807–812.
   PubMed Web of Science ®Google Scholar
• Ferreira R, Wai A, Shimizu R, et al. Dynamic regulation of Gata factor levels is more important than their identity. Blood. 2007;109:5481–5490.
   PubMed Web of Science ®Google Scholar
• Nicolis S, Bertini C, Ronchi A, et al. An erythroid specific enhancer upstream to the gene encoding the cell-type specific transcription factor GATA-1. Nucleic Acids Res. 1991;19:5285–5291.
   PubMed Web of Science ®Google Scholar
• Ferreira R, Ohneda K, Yamamoto M, et al. GATA1 function, a paradigm for transcription factors in hematopoiesis. Mol Cell Biol. 2005;25:1215–1227.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Yamamoto M. Regulation of GATA1 gene expression. J Biochem. 2007;142:1–10.
   PubMed Web of Science ®Google Scholar
• Guyot B, Murai K, Fujiwara Y, et al. Characterization of a megakaryocyte-specific enhancer of the key hemopoietic transcription factor GATA1. J Biol Chem. 2006;281:13733–13742.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Onodera K, Motohashi H, et al. Arrest in primitive erythroid cell development caused by promoter-specific disruption of the GATA-1 gene. J Biol Chem. 1997;272:12611–12615.
   PubMed Web of Science ®Google Scholar
• McDevitt MA, Shivdasani RA, Fujiwara Y, et al. A “knockdown” mutation created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc Natl Acad Sci U S A. 1997;94:6781–6785.
   PubMed Web of Science ®Google Scholar
• Shimizu R, Kuroha T, Ohneda O, et al. Leukemogenesis caused by incapacitated GATA-1 function. Mol Cell Biol. 2004;24:10814–10825.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Bianchi L, Cellai C, et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood. 2002;100:1123–1132.
   PubMed Web of Science ®Google Scholar
• Ghinassi B, Sanchez M, Martelli F, et al. The hypomorphic Gata1low mutation alters the proliferation/differentiation potential of the common megakaryocytic-erythroid progenitor. Blood. 2007;109:1460–1471.
   PubMed Web of Science ®Google Scholar
• Noh JY, Gandre-Babbe S, Wang Y, et al. Inducible Gata1 suppression expands megakaryocyte-erythroid progenitors from embryonic stem cells. J Clin Invest. 2015;125:2369–2374.
   PubMed Web of Science ®Google Scholar
• Eliades A, Papadantonakis N, Bhupatiraju A, et al. Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase. J Biol Chem. 2011;286:27630–27638.
   PubMed Web of Science ®Google Scholar
• Martelli F, Ghinassi B, Panetta B, et al. Variegation of the phenotype induced by the Gata1low mutation in mice of different genetic backgrounds. Blood. 2005;106:4102–4113.
   PubMed Web of Science ®Google Scholar
• Migliaccio AR, Martelli F, Verrucci M, et al. Gata1 expression driven by the alternative HS2 enhancer in the spleen rescues the hematopoietic failure induced by the hypomorphic Gata1low mutation. Blood. 2009;114:2107–2120.
   PubMed Web of Science ®Google Scholar
• Zingariello M, Sancillo L, Martelli F, et al. The thrombopoietin/MPL axis is activated in the Gata1low mouse model of myelofibrosis and is associated with a defective RPS14 signature. Blood Cancer J. 2017;7:e572.
   PubMed Web of Science ®Google Scholar
• Migliaccio AR, Martelli F, Verrucci M, et al. Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. Exp Hematol. 2008;36:158–171.
   PubMed Web of Science ®Google Scholar
• Zingariello M, Martelli F, Ciaffoni F, et al. Characterization of the TGF-beta1 signaling abnormalities in the Gata1low mouse model of myelofibrosis. Blood. 2013;121:3345–3363.
   PubMed Web of Science ®Google Scholar
• Yang Y, Akada H, Nath D, et al. Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm. Blood. 2016;127:3410–3423.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Kubovcakova L, Nienhold R, et al. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. J Exp Med. 2016;213:1479–1496.
   PubMed Web of Science ®Google Scholar
• Marty C, Harini N, Pecquet C, et al. Calr mutants retroviral mouse models lead to a myeloproliferative neoplasm mimicking an essential thrombocythemia progressing to a myelofibrosis. Blood. 2014;124:157.
   PubMed Web of Science ®Google Scholar
• Akada H, Yan D, Zou H, et al. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010;115:3589–3597.
   PubMed Web of Science ®Google Scholar
• Li J, Spensberger D, Ahn JS, et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood. 2010;116:1528–1538.
   PubMed Web of Science ®Google Scholar
• Bumm TG, Elsea C, Corbin AS, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res. 2006;66:11156–11165.
   PubMed Web of Science ®Google Scholar
• Lacout C, Pisani DF, Tulliez M, et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108:1652–1660.
   PubMed Web of Science ®Google Scholar
• Wernig G, Mercher T, Okabe R, et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107:4274–4281.
   PubMed Web of Science ®Google Scholar
• Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.
   PubMed Web of Science ®Google Scholar
• Frey BM, Rafii S, Teterson M, et al. Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis. J Immunol. 1998;160:691–699.
   PubMed Web of Science ®Google Scholar
• Kakumitsu H, Kamezaki K, Shimoda K, et al. Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. Leuk Res. 2005;29:761–769.
   PubMed Web of Science ®Google Scholar
• Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood. 1997;90:4369–4383.
   PubMed Web of Science ®Google Scholar
• Ulich TR, Del Castillo J, Senaldi G, et al. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood. 1996;87:5006–5015.
   PubMed Web of Science ®Google Scholar
• Erslev AJ, Wilson J, Caro J. Erythropoietin titers in anemic, nonuremic patients. J Lab Clin Med. 1987;109:429–433.
   PubMed Web of Science ®Google Scholar
• Bauer A, Tronche F, Wessely O, et al. The glucocorticoid receptor is required for stress erythropoiesis. Genes Dev. 1999;13:2996–3002.
   PubMed Web of Science ®Google Scholar
• Tajima Y, Moore MA, Soares V, et al. Consequences of exclusive expression in vivo of Kit-ligand lacking the major proteolytic cleavage site. Proc Natl Acad Sci U S A. 1998;95:11903–11908.
   PubMed Web of Science ®Google Scholar
• Paulson RF, Shi L, Wu DC. Stress erythropoiesis: new signals and new stress progenitor cells. Curr Opin Hematol. 2011;18:139–145.
   PubMed Web of Science ®Google Scholar
• Gao X, Lee HY, Da Rocha EL, et al. TGF-beta inhibitors stimulate red blood cell production by enhancing self-renewal of BFU-E erythroid progenitors. Blood. 2016;128:2637–2641.
   PubMed Web of Science ®Google Scholar
• Perry JM, Harandi OF, Paulson RF. BMP4, SCF, and hypoxia cooperatively regulate the expansion of murine stress erythroid progenitors. Blood. 2007;109:4494–4502.
   PubMed Web of Science ®Google Scholar
• Gursoy A, Dogruk Unal A, Ayturk S, et al. Polycythemia as the first manifestation of Cushing’s disease. J Endocrinol Invest. 2006;29:742–744.
   PubMed Web of Science ®Google Scholar
• Ellis H. Thomas Addison: Addisonian (pernicious) anaemia, Addison’s disease of the suprarenal gland. J Perioper Pract. 2013;23:31–32.
   PubMedGoogle Scholar
• Ramos P, Casu C, Gardenghi S, et al. Macrophages support pathological erythropoiesis in polycythemia vera and beta-thalassemia. Nat Med. 2013;19:437–445.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Bianchi L, Cellai C, et al. Accentuated response to phenylhydrazine and erythropoietin in mice genetically impaired for their GATA-1 expression (GATA-1(low) mice). Blood. 2001;97:3040–3050.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Paoletti F, Linari S, et al. Identification and characterization of a bipotent (erythroid and megakaryocytic) cell precursor from the spleen of phenylhydrazine-treated mice. Blood. 2000;95:2559–2568.
   PubMed Web of Science ®Google Scholar
• Sanchez M, Weissman IL, Pallavicini M, et al. Differential amplification of murine bipotent megakaryocytic/erythroid progenitor and precursor cells during recovery from acute and chronic erythroid stress. Stem Cells. 2006;24:337–348.
   PubMed Web of Science ®Google Scholar
• Belay E, Miller CP, Kortum AN, et al. A hyperactive Mpl-based cell growth switch drives macrophage-associated erythropoiesis through an erythroid-megakaryocytic precursor. Blood. 2015;125:1025–1033.
   PubMed Web of Science ®Google Scholar
• Vyas P, Ault K, Jackson CW, et al. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood. 1999;93:2867–2875.
   PubMed Web of Science ®Google Scholar
• Centurione L, Di Baldassarre A, Zingariello M, et al. Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice. Blood. 2004;104:3573–3580.
   PubMed Web of Science ®Google Scholar
• Zingariello M, Fabucci ME, Bosco D, et al. Differential localization of P-selectin and von Willebrand factor during megakaryocyte maturation. Biotech Histochem. 2010;85:157–170.
   PubMed Web of Science ®Google Scholar
• Hop C, Guilliatt A, Daly M, et al. Assembly of multimeric von Willebrand factor directs sorting of P-selectin. Arterioscler Thromb Vasc Biol. 2000;20:1763–1768.
   PubMed Web of Science ®Google Scholar
• Denis CV, Andre P, Saffaripour S, et al. Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice. Proc Natl Acad Sci U S A. 2001;98:4072–4077.
   PubMed Web of Science ®Google Scholar
• Italiano JE Jr., Richardson JL, Patel-Hett S, et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood. 2008;111:1227–1233.
   PubMed Web of Science ®Google Scholar
• Schmitt A, Jouault H, Guichard J, et al. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood. 2000;96:1342–1347.
   PubMed Web of Science ®Google Scholar
• Thiele J, Lorenzen J, Manich B, et al. Apoptosis (programmed cell death) in idiopathic (primary) osteo-/myelofibrosis: naked nuclei in megakaryopoiesis reveal features of para-apoptosis. Acta Haematol. 1997;97:137–143.
   PubMed Web of Science ®Google Scholar
• Schmitt A, Drouin A, Masse JM, et al. Polymorphonuclear neutrophil and megakaryocyte mutual involvement in myelofibrosis pathogenesis. Leuk Lymphoma. 2002;43:719–724.
   PubMed Web of Science ®Google Scholar
• Alvarez-Larran A, Arellano-Rodrigo E, Reverter JC, et al. Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. Ann Hematol. 2008;87:269–276.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Bianchi L, Paoletti F, et al. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. Blood. 2005;105:3493–3501.
   PubMed Web of Science ®Google Scholar
• Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001;98:2720–2725.
   PubMed Web of Science ®Google Scholar
• Kacena MA, Shivdasani RA, Wilson K, et al. Megakaryocyte-osteoblast interaction revealed in mice deficient in transcription factors GATA-1 and NF-E2. J Bone Miner Res. 2004;19:652–660.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Pancrazzi A, Guglielmelli P, et al. Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. Am J Pathol. 2005;167:849–858.
   PubMed Web of Science ®Google Scholar
• Grinfeld J, Nangalia J, Green AR. Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. Haematologica. 2017;102:7–17.
   PubMed Web of Science ®Google Scholar
• Bersenev A, Wu C, Balcerek J, et al. Lnk constrains myeloproliferative diseases in mice. J Clin Invest. 2010;120:2058–2069.
   PubMed Web of Science ®Google Scholar
• Wang X, Prakash S, Lu M, et al. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest. 2012;122:3888–3899.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Kantarjian HM, Kiladjian -J-J, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100:1139–1145.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115:3109–3117.
   PubMed Web of Science ®Google Scholar
• Verrucci M, Pancrazzi A, Aracil M, et al. CXCR4-independent rescue of the myeloproliferative defect of the Gata1(low) myelofibrosis mouse model by Aplidin(®). J Cell Physiol. 2010;225:490–499.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Tefferi A, Guglielmelli P, et al. Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial. Blood Cancer J. 2015;5:e286.
   PubMed Web of Science ®Google Scholar
• Abdelouahab H, Zhang Y, Wittner M, et al. CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner. Oncotarget. 2017;8:54082–54095.
   PubMedGoogle Scholar
• Ciurea SO, Merchant D, Mahmud N, et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood. 2007;110:986–993.
   PubMed Web of Science ®Google Scholar
• Chagraoui H, Komura E, Tulliez M, et al. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100:3495–3503.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Villeval J-L, Wagner-Ballon O, et al. Animal models of myelofibrosis. In: Conn PM, editor. Sourcebook of models for biomedical research. Totowa (NJ): Humana Press; 2008. p. 713–723.
   Google Scholar
• Vainchenker W, Constantinescu SN, Plo I. Recent advances in understanding myelofibrosis and essential thrombocythemia. F1000Research. 2016;5: F1000. Faculty Rev-700.
   PubMedGoogle Scholar
• Yue L, Bartenstein M, Zhao W, et al. Efficacy of ALK5 inhibition in myelofibrosis. JCI Insight. 2017;2:e90932.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Li T, Sandy L, et al. Anti-transforming growth factor-beta therapy in patients with myelofibrosis. Leuk Lymphoma. 2014;55:450–452.
   PubMed Web of Science ®Google Scholar
• Ceglia I, Dueck AC, Masiello F, et al. Preclinical rationale for TGF-beta inhibition as a therapeutic target for the treatment of myelofibrosis. Exp Hematol. 2016;44:1138–1155.e4.
   PubMed Web of Science ®Google Scholar
• Ciaffoni F, Cassella E, Varricchio L, et al. Activation of non-canonical TGF-beta1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis. Blood Cells Mol Dis. 2015;54:234–241.
   PubMed Web of Science ®Google Scholar
• Wernig G, Chen SY, Cui L, et al. Unifying mechanism for different fibrotic diseases. Proc Natl Acad Sci U S A. 2017;114:4757–4762.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Manshouri T, Pilling D, et al. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med. 2016;213:1723–1740.
   PubMed Web of Science ®Google Scholar
• Zetterberg E, Verrucci M, Martelli F, et al. Abnormal P-selectin localization during megakaryocyte development determines thrombosis in the gata1low model of myelofibrosis. Platelets. 2014;25:539–547.
   PubMed Web of Science ®Google Scholar
• Spangrude GJ, Lewandowski D, Martelli F, et al. P-selectin sustains extramedullary hematopoiesis in the gata1 low model of myelofibrosis. Stem Cells. 2016;34:67–82.
   PubMed Web of Science ®Google Scholar
• Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376:429–439.
   PubMed Web of Science ®Google Scholar
• Gerber EE, Gallo EM, Fontana SC, et al. Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature. 2013;503:126–130.
   PubMed Web of Science ®Google Scholar
• Akhmetshina A, Palumbo K, Dees C, et al. Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat Commun. 2012;3:735.
   PubMed Web of Science ®Google Scholar
• Barosi G. An immune dysregulation in MPN. Curr Hematol Malig Rep. 2014;9:331–339.
   PubMed Web of Science ®Google Scholar
• Massa M, Campanelli R, Fois G, et al. Reduced frequency of circulating CD4+CD25brightCD127lowFOXP3+ regulatory T cells in primary myelofibrosis. Blood. 2016;128:1660–1662.
   PubMed Web of Science ®Google Scholar
• Marin Oyarzún CP, Carestia A, Lev PR, et al. Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms. Sci Rep. 2016;6:38738.
   PubMed Web of Science ®Google Scholar